These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 28669849

  • 21. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L, Lin Z, Li N, Jiang J, Lu C, Du S, Zhang J, Wang Y, Chen J, Gong P.
    Zhongguo Fei Ai Za Zhi; 2021 Sep 20; 24(9):623-631. PubMed ID: 34455737
    [Abstract] [Full Text] [Related]

  • 22. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
    Zheng Q, Huang Y, Zeng X, Chen X, Shao S, Jin Y, Xue Q, Wang Y, Guo Y, Gu B, Wu C, Li Y.
    J Cancer Res Clin Oncol; 2021 May 20; 147(5):1547-1556. PubMed ID: 33196892
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.
    Chen M, Xu Y, Zhao J, Li J, Liu X, Zhong W, Wang M.
    Thorac Cancer; 2021 Sep 20; 12(17):2339-2344. PubMed ID: 34291566
    [Abstract] [Full Text] [Related]

  • 25. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
    Mei P, Shilo K, Wei L, Shen R, Tonkovich D, Li Z.
    Cancer Cytopathol; 2019 Jul 20; 127(7):447-457. PubMed ID: 31025831
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.
    Clin Lung Cancer; 2017 Sep 20; 18(5):572-582.e1. PubMed ID: 28318951
    [Abstract] [Full Text] [Related]

  • 28. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.
    Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scott M, Scorer P, Al-Masri H, Rebelatto MC, Walker J.
    Clin Cancer Res; 2017 Jul 15; 23(14):3585-3591. PubMed ID: 28073845
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
    Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH.
    J Cancer Res Clin Oncol; 2021 Aug 15; 147(8):2459-2469. PubMed ID: 33523301
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.
    Kuempers C, van der Linde LIS, Reischl M, Vogel W, Stellmacher F, Reck M, Heigener D, Rabe KF, Kirfel J, Perner S, Welker L.
    Virchows Arch; 2020 Feb 15; 476(2):261-271. PubMed ID: 31392467
    [Abstract] [Full Text] [Related]

  • 35. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X.
    Clin Lung Cancer; 2015 Sep 15; 16(5):e25-35. PubMed ID: 25801750
    [Abstract] [Full Text] [Related]

  • 36. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
    Téglási V, Pipek O, Lózsa R, Berta K, Szüts D, Harkó T, Vadász P, Rojkó L, Döme B, Bagó AG, Tímár J, Moldvay J, Szállási Z, Reiniger L.
    Clin Lung Cancer; 2019 Sep 15; 20(5):363-369.e2. PubMed ID: 31178388
    [Abstract] [Full Text] [Related]

  • 37. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R, Murakami S, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Kusumoto M, Yamamoto N, Ohe Y.
    Med Oncol; 2019 Apr 27; 36(6):49. PubMed ID: 31030326
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J.
    Diagn Pathol; 2016 Oct 08; 11(1):95. PubMed ID: 27717372
    [Abstract] [Full Text] [Related]

  • 40. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R, Giovacchini CX, Liu B, Green CL, Clarke JM, Mahmood K, Pavlisko EN.
    J Am Soc Cytopathol; 2020 Oct 08; 9(6):485-493. PubMed ID: 32336671
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.